Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.

[1]  P. Rose,et al.  Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. , 2008, Gynecologic oncology.

[2]  S. Yamada,et al.  A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. , 2007, Gynecologic oncology.

[3]  P. Thall,et al.  Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  S. Rodenhuis,et al.  Severe pulmonary toxicity in patients with leiomyosarcoma after treatment with gemcitabine and docetaxel , 2007, Investigational New Drugs.

[5]  J. Blay,et al.  Docetaxel and gemcitabine combination in 133 advanced soft‐tissue sarcomas: A retrospective analysis , 2006, International journal of cancer.

[6]  A. Yoshimura,et al.  Docetaxel in Combination with Either Cisplatin or Gemcitabine in Unresectable Non-small Cell Lung Carcinoma: A Randomized Phase II Study by the Japan Lung Cancer Cooperative Clinical Study Group , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  S. Belknap,et al.  Clinical features and correlates of gemcitabine‐associated lung injury , 2006, Cancer.

[8]  J. Maurel,et al.  A phase II trial of temozolomide as a 6‐week, continuous, oral schedule in patients with advanced soft tissue sarcoma , 2005, Cancer.

[9]  J. Manola,et al.  Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  D. Ettinger,et al.  Soft tissue sarcoma clinical practice guidelines in oncology. , 2005, Journal of the National Comprehensive Cancer Network : JNCCN.

[11]  S. Agelaki,et al.  High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study. , 2004, Lung cancer.

[12]  J. Lucci,et al.  Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study. , 2004, Gynecologic oncology.

[13]  B. Anderson,et al.  A phase II clinical trial of diaziquone (AZQ) in the treatment of patients with recurrent leiomyosarcoma of the uterus , 1991, Investigational New Drugs.

[14]  M. Morgan,et al.  Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study. , 2003, Gynecologic oncology.

[15]  E. Venkatraman,et al.  Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Blessing,et al.  Trimetrexate in the treatment of recurrent or advanced leiomyosarcoma of the uterus: a phase II study of the Gynecologic Oncology Group. , 2002, Gynecologic oncology.

[17]  E. Raymond,et al.  Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Mannel,et al.  Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study. , 2000, American journal of clinical oncology.

[19]  G. Sutton,et al.  Phase II trial of paclitaxel in leiomyosarcoma of the uterus: a gynecologic oncology group study. , 1996, Gynecologic oncology.

[20]  T T Chen,et al.  Optimal flexible designs in phase II clinical trials. , 1998, Statistics in medicine.

[21]  P. Rose,et al.  Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study. , 1998, Gynecologic oncology.

[22]  R. Buller,et al.  Amonafide in patients with leiomyosarcoma of the uterus: a phase II Gynecologic Oncology Group study. , 1998, American journal of clinical oncology.

[23]  G. Sutton,et al.  Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. , 1996, Gynecologic oncology.

[24]  J. Verweij,et al.  Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  G. Sutton,et al.  Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. , 1992, American journal of obstetrics and gynecology.

[26]  E. Yordan,et al.  Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  S. Mineishi,et al.  A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  H. Kantarjian,et al.  Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia. , 1990, Cancer research.

[29]  H. Muss,et al.  Mitoxantrone in the Treatment of Advanced Uterine Sarcoma: A Phase II Trial of the Gynecologic Oncology Group , 1990, American journal of clinical oncology.

[30]  J. Blessing,et al.  Phase II trial of etoposide in the management of advanced and recurrent leiomyosarcoma of the uterus: a Gynecologic Oncology Group Study. , 1987, Cancer treatment reports.

[31]  R. Zaino,et al.  A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas , 1983, Cancer.